Lower rate of progression to clinical type 1 diabetes after teplizumab treatment

Progression to clinical (stage 3) type 1 diabetes in individuals with preclinical (stage 2) disease who were randomly assigned to treatment with teplizumab or placebo. The number of participants who progressed to clinical type 1 diabetes is shown for the initial trial analysis and after extended follow-up.